Key statistics
On Thursday, HUTCHMED (China) Ltd (13:HKG.HS) closed at 31.35, -12.67% below its 52-week high of 35.90, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.30 |
---|---|
High | 32.80 |
Low | 31.05 |
Bid | 31.30 |
Offer | 31.35 |
Previous close | 30.65 |
Average volume | 5.57m |
---|---|
Shares outstanding | 871.47m |
Free float | 501.20m |
P/E (TTM) | -- |
Market cap | 27.32bn HKD |
EPS (TTM) | -0.3881 HKD |
Data delayed at least 15 minutes, as of Oct 10 2024.
More ▼
Announcements
- HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
- HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
- HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
- HUTCHMED Reports 2024 Interim Results and Provides Business Updates
- HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
- HUTCHMED to Announce 2024 Half-Year Financial Results
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
More ▼